AGP Executive Report
Last update: 10 hours agoCancer Care & Pharma: Bayer won FDA approval for oral HER2 inhibitor Hyrnuo (sevabertinib) as a first-line option for advanced HER2-mutant non-small cell lung cancer, moving it earlier in treatment and intensifying competition with other oral HER2 drugs. Respiratory Health: Celltrion says its asthma/allergy biosimilar Omlyclo is now sold in 26 European countries, with Italy sales above initial targets and Spain surpassing a 90% share of the omalizumab market. Infectious Disease Watch: West Nile virus is driving new deaths in the Netherlands, with infections rising to 18 and more fatalities reported; cases have also climbed in Greece and Italy. Public Health & Climate: A UN climate official warns Europe’s extreme heat is already costing lives and worsening health risks, with heat-related excess deaths reported across countries including Germany and Spain. Wellness & Care Culture: A new report on AI at work finds professionals want AI to support decisions, but say human judgment, ethics, critical thinking and empathy must be protected. Italy-Linked Health Access: Italy appeals for blood donors as stocks run critically low over summer.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
